Form 4: ACUR Director Ross Exchanges RSUs, Receives New Grant

Acura Pharmaceuticals Director George K. Ross reported an exchange of restricted stock units for common stock and received a new RSU grant.

Summary

• Director George K. Ross reported transactions involving Acura Pharmaceuticals, Inc. common stock and restricted stock units.
• On January 2, 2026, Ross exchanged 50,000 restricted stock units (granted January 2, 2025) for 50,000 shares of common stock, paying a par value of $0.01 per share.
• Following this exchange, Ross's direct beneficial ownership of common stock increased to 595,903 shares.
• Concurrently, Ross received a new grant of 50,000 restricted stock units under the 2021 Plan.
• These newly granted RSUs will vest 25% on the last day of March, June, September, and December 2026.
• Vested RSUs will be exchanged on a one-for-one basis for common stock (upon payment of par value) or up to 40% may be elected for cash, with distributions on the first business day of January 2027, or earlier upon a change of control.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine insider transaction reporting equity compensation, which is generally seen as a positive for aligning management interests with shareholders. No significant negative or positive news beyond this.

Positives

• Director George K. Ross received a new grant of 50,000 Restricted Stock Units, indicating continued equity-based compensation and alignment with shareholder interests.
• The exchange of previously vested RSUs for common stock increases the director's direct ownership of company shares, further aligning his interests with the company's performance.

Future Outlook

The newly granted 50,000 Restricted Stock Units will vest quarterly throughout 2026, with distributions of vested units scheduled for the first business day of January 2027, or earlier upon a change of control. The reporting person has the option to elect up to 40% cash for the distribution of these RSUs.

Industry Context

This Form 4 filing reflects a routine equity compensation event for a director, common practice across publicly traded companies to align management incentives with shareholder value through stock-based awards.

Corporate Governance

Related Party Transactions

• The exchange of restricted stock units for common stock and the grant of new restricted stock units to Director George K. Ross constitute related party transactions as they involve a director and the company, consistent with standard equity compensation practices.

Stakeholder Impact

• Shareholders: The grant of new RSUs to a director can be viewed positively as it aligns management's long-term interests with shareholder value creation.
• Employees: The 2021 Plan provides a framework for equity compensation, potentially impacting other employees if similar plans are in place.

Next Steps

• Vesting of 25% of the 50,000 Restricted Stock Units on the last day of March, June, September, and December 2026.
• Distribution of vested Restricted Stock Units on the first business day of January 2027, or earlier upon a change of control.

Key Dates

Keywords

Acura Pharmaceuticals, ACUR, George K. Ross, Form 4, Insider Transaction, Restricted Stock Units, RSU, Common Stock, Equity Compensation, Director